SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema

Sanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture.